Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors

I.E.L.M. Kuppens; P.O. Witteveen; M. Schot; V.M. Schuessler; A. Daehling; J.H. Beijnen; E.E. Voest; J.H.M. Schellens

Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors

Translated title of the contribution: Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors

I.E.L.M. Kuppens, P.O. Witteveen, M. Schot, V.M. Schuessler, A. Daehling, J.H. Beijnen, E.E. Voest, J.H.M. Schellens

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors
Original language	Undefined/Unknown
Pages (from-to)	227-235
Number of pages	9
Journal	Investigational New Drugs
Volume	25
Issue number	3
Publication status	Published - 2007

Cite this

@article{8c6c2c5944a4499e86a8af0a9d2b35f8,

title = "Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors",

author = "I.E.L.M. Kuppens and P.O. Witteveen and M. Schot and V.M. Schuessler and A. Daehling and J.H. Beijnen and E.E. Voest and J.H.M. Schellens",

note = "0167-6997",

year = "2007",

language = "Undefined/Unknown",

volume = "25",

pages = "227--235",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors

AU - Kuppens, I.E.L.M.

AU - Witteveen, P.O.

AU - Schot, M.

AU - Schuessler, V.M.

AU - Daehling, A.

AU - Beijnen, J.H.

AU - Voest, E.E.

AU - Schellens, J.H.M.

N1 - 0167-6997

PY - 2007

Y1 - 2007

M3 - Article

SN - 0167-6997

VL - 25

SP - 227

EP - 235

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -